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(29%) met BP targets (< 130/80mmHg), 50% had BP ≥ 140/90mmHg. HbA1c, LDL and 
BP were well-controlled in approximately 7.2%, 41.2%, and 8.6% of patients, respec-
tively, while 59.2%, 7.8% and 21.3% of patients were never-controlled, respectively. 
The proportion of patients who were never-controlled for HbA1c increased with 
T2DM duration. ConClusions: Nearly 75% of patients met targets and over 40% 
were well-controlled for LDL; however, rates of control for HbA1c and BP were lower. 
Given the increased risk of complications associated with poor control, achieving 
higher rates of control could reduce the burden of T2DM in the UAE.
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A SyStemAtic Review AnD netwoRk metA-AnAlySiS of SeconD-line 
Anti-DiABeteS tReAtmentS foR thoSe with tyPe 2 DiABeteS mellituS 
inADequAtely contRolleD By SulfonyluReA monotheRAPy
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objeCtives: To assess the efficacy and safety of EU-licensed anti-diabetes agents 
when added to sulfonylurea (SU). Methods: A systematic review was conducted in 
MEDLINE, EMBASE and CENTRAL to identify randomised controlled trials in patients 
with type 2 diabetes mellitus inadequately controlled by a stable dose of SU mono-
therapy. Direct meta-analysis, Bucher indirect comparisons and Bayesian network 
meta-analysis (NMA) using WinBUGs were conducted. The effect of potentially con-
founding baseline factors was explored through covariate analyses. Results: The 
search identified 2,976 articles of which 2,945 were excluded based on title/abstract. 
On reviewing remaining full-text articles, 5 studies were selected for analysis at 24 
(+/- 6) weeks follow-up. All studies were comparable in terms of baseline charac-
teristics, including: HbA1c, age and BMI. Three classes of agents had sufficient data 
for meta-analysis: DPP4 inhibitors (‘DPP4s’), GLP1 analogues (‘GLP1s’) and SGLT2 
inhibitors (‘SGLT2s’; only dapagliflozin has an EU licence in this class). Based on the 
fixed-effect NMA, all three classes of treatment resulted in statistically significantly 
lower HbA1c at follow-up compared to placebo (based on the 95% credible interval 
[CrI]). SGLT2 treatment resulted in significantly lower weight at follow-up compared 
to placebo (–1.54 kg; 95% CrI –2.16, –0.92), which is in contrast to treatment with 
GLP1s (-0.65kg; 95% CrI -1.37, 0.07) and DPP4s (0.57 kg; 95% CrI 0.09, 1.06). The odds 
of hypoglycaemia for SGLT2 and DPP4 add-on treatment were similar to placebo, but 
significantly greater than placebo for GLP1 add-on treatment (10.89; 95% CrI 4.24, 
38.28). Assessment of NMA model heterogeneity was hindered by the low number 
of studies within the network. ConClusions: All three classes of treatments used 
as add-on therapy to SU provided better short-term glycaemic control compared to 
SU monotherapy. However, DPP4s, GLP1s and SGLT2s may show variation in terms 
of impact on weight and incidence of hypoglycaemia.
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objeCtives: In RCTs performed in patients with T2DM liraglutide reduced HbA1c 
by 1.0-1.5%-point and weight up to 3.7kg. Patients had disease duration of 7.7 years 
on average, baseline HbA1c of 8.4%. We assessed the effectiveness of liraglutide 
prescribed per guidelines in the analyzed cohort. Methods: Patients from an Israeli 
HMO (Maccabi) treated with liraglutide ≥ 6 months during 2010-2012 were included. 
Prescription rules were BMI> 30; HbA1c> 8.0% after use of 2 oral hypoglycemic 
agents. Data was extracted from electronic records included in a registry of > 90,000 
diabetes patients. Assessments were performed within 180 days before the date of 
first prescription and at 6 months +/- 90 days. Results: A total of 462 insulin naïve 
patients treated with liraglutide were identified. 52% males; age was 61.0 years (SD 
8.67); diabetes duration was 10.5 years (SD 3.53). HbA1c decreased by 0.93%-points 
(SD 1.17) (p< 0.0001 95% CI 0.82-1.03), down from 8.6% (SD 1.20). Mean time between 
HbA1c measurements was 222 days (SD 52.39). In 170 patients with available data, 
weight decreased by 2.5kg (SD 5.09) (p< 0.0001 95% CI 1.71-3.2) from 99.9kg (18.17). 
Time between measurements of weight was 202 days (SD 63.2). Diabetes duration, 
HbA1c levels and change of the group with weight data were similar to the main 
cohort. 202 patients (43.7%) achieved ≥ 1%-point HbA1c reduction. In 31.2% (48 of 
170), the reduction was without weight gain. 26 (16.9%) achieved the NICE criteria 
(decrease of HbA1c≥ 1% and weight≥ 3%). Baseline HbA1c and amount of liraglutide 
prescribed correlated with the degree of HbA1c reduction. ConClusions: Real life 
use of liraglutide significantly reduced HbA1c and weight, showing similar outcomes 
as those observed in RCTs. Compared to the RCTs patients in this cohort had more 
severe diabetes and were more obese, yet liraglutide retained its effects.
PDB10
A BAyeSiAn multiPle tReAtment comPARiSon of Duloxetine, 
PRegABAlin, gABAPentin, AmitRiPtyline, AnD theiR comBinAtionS foR 
PAinful PeRiPheRAl neuRoPAthy BASeD on PAin ReDuction RePoRteD in 
clinicAl tRAilS
Chinthammit C., Malone D.
University of Arizona, Tucson, AZ, USA
objeCtives: To compare the performance of treatment of painful diabetic periph-
eral neuropathy (PDPN) — duloxetine, pregabalin, gabapentin, amitriptyline, and 
their combinations based upon pain reduction reported in clinical trials, and inform 
a revised treatment algorithm. Methods: Published studies of PDPN treatment 
through May 2012 were identified from MEDLINE(PubMed) database and extended 
manual search was conducted based on citations from identified studies. Inclusion 
criteria was restricted to randomized controlled trials lasting at least 5 weeks and at 
most 12 weeks and studies examining 30% pain reduction or equivalent. Direct and 
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objeCtives: The 15197:2003 ISO states that 95% of the glucose results shall fall within 
±15 mg/dl of the concentrations ≤ 75 mg/dl and ±20% at those > 75 mg/dl. The objec-
tive was to estimate the 1-year economic impact for the Spanish Health System of 
blood glucose self-monitoring by using glucose meters with different degrees of accu-
racy Methods: A probabilistic model was designed to estimate the clinical and eco-
nomic outcomes of a type 2 (T2D) or type 1 diabetes (T1D) cohort. A second-order Monte 
Carlo simulation was run, in order to estimate the frequency of non-detected hypoglyce-
mia and hyperglycemia cases. The frequency of macro and microvascular events, associ-
ated with the non-detected readings, was calculated. Finally, the economic impact was 
assessed for better accuracy levels (±15; ±5%) Results: We estimated a total prevalence 
of 96,169 type 1 and 3,115,866 type 2 treated diabetic patients in Spain. We included all 
the T1D patients and those insulin dependents T2D (23.4%). The average annual cost of 
associated events and those of monitoring blood glucose were estimated at 95,987,193 
€ for T2D and 11,501,292 € for T1D with a ±20% accuracy. When an accuracy of ±15% 
was analyzed, the annual costs for T2D were reduced to 88,349,485 € and to 9,180,317 € 
for T1D, showing a total saving of 9,958,682 € a year. If the accuracy rose up to ±5%, the 
results were 80,067,179 € in T2D and 6,084,776 € in T1D, for a total saving of 21,336.530 
€ a year. The total costs reduced by 9.3%, 15.4% and 19.9% with accuracy of ±15%, ±10% 
and ±5%, respectively, respect of the initial ±20% ConClusions: This study shows that 
if the accuracy of the glucose meters raises, several macrovascular and microvascular 
events and hypoglycemic episodes could be avoided. That can improve patients’ quality 
of life and reduce significantly the associated costs
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BASeline chARActeRiSticS, weight AnD glycAemic chAnge Among 
PAtientS in the uniteD kingDom with tyPe 2 DiABeteS mellituS (t2Dm) 
PReScRiBeD A new AntiDiABetic tReAtment clASS in A ReAl woRlD 
Setting
Blak B.T.1, Rigney U.1, Ycas J.2, Racketa J.2, Hammar N.3
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objeCtives: Patients with T2DM have an increased risk of comorbidities associ-
ated with weight gain. Depending on patients’ weight, treatment guidelines give 
preference to treatments that have favourable weight profiles, with weight gain 
being an important adverse event to avoid. This study aims to characterize baseline 
characteristics, weight and glycaemic change in patients prescribed new antidia-
betic treatment. Methods: Patients with T2DM diagnosis and receiving first new 
antidiabetic treatment class (index) between 01/01/05-01/01/12 were identified in 
UK CPRD primary care records. Index class could be first-line, switch or add-on. 
Demographics, baseline weight and glycosylated haemoglobin (HbA1c), and change 
at 6 months were described by index class. Results: Of 23,987 included (of whom 
133 were lost to follow-up) 64.7% initiated metformin (MET), 15.5% sulfonylureas 
(SU), (14.0%) thiazolidinediones (TZD), 2.1% dipeptidyl-peptidase-4-inhibitors (DPP4), 
1.9% insulin, 0.7% glucagon-like-peptide-1-agonists (GLP-1), 0.6% ‘other’, 0.5% acar-
bose. About 57% were men; baseline mean age for different index classes ranged 
between 56.5 (insulin) and 63.1 years (acarbose). Mean baseline weight ranged 
between 88.0 (SU) and 112.4 kg (GLP-1) and mean baseline HbA1c between 72.6 
mmol/mol (8.8%) (acarbose) and 84.7 mmol/mol (9.9%) (insulin). Among 14,438 
patients with six-month follow-up data an increase in weight was found for sub-
jects initiating SU (2.1%;95%CI: 1.9;2.4,n= 2,223), TZD (1.9%;95%CI: 1.7;2.1,n= 2,034) 
and insulin (1.8% ;95%CI: 1.0;2.6,n= 285). A reduction in weight was observed for 
patients on GLP-1 (-3.4%;95%CI: -4.3;-2.5,n= 119), DPP4 (-0.9%;95%CI: -1.4;-0.4,n= 347) 
and MET (-0.8%;95%CI: -0.9;-0.7,n= 9,278). A mean reduction in HbA1c over the six 
month period was seen for all antidiabetic classes but was not statistical significant 
for GLP-1 and ‘other’. ConClusions: These results indicate that initiation of anti-
diabetic agents such as SU, TZD and insulin frequently are associated with weight 
gain. This underscores the need to choose agents with favourable weight profiles for 
overweight or obese patients, as recommended by UK T2DM treatment guidelines.
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objeCtives: Inadequate glycemic, blood pressure (BP), and lipid control among 
type 2 diabetes mellitus (T2DM) patients is associated with increased risk of T2DM-
related complications. Few data on these outcomes are available from the United 
Arab Emirates (UAE). The objective was to estimate the proportion of T2DM patients 
with glycemic, lipid, and BP control at a large centre in Dubai. Methods: Charts 
from T2DM patients aged ≥ 18 years that visited the Dubai Hospital from October 
2009 to March 2010 (enrolment period) were systematically sampled until the target 
(n= 250) was reached. Results of haemoglobin A1c (HbA1c), low-density lipoprotein 
(LDL), and BP tests conducted from enrolment to September 2011 were abstracted 
from patient charts. The most recent test values were compared to guideline targets. 
The proportion of well-controlled (target met on all tests) and never-controlled 
patients (target not met on any test) over the study period was calculated. All analy-
ses were stratified by T2DM duration. Results: Thirty-three percent of the sample 
was male, and at enrolment, the mean (SD) age was 58 years (12), and T2DM dura-
tion, 14 years (8). At the most recent assessment, 58 patients (23%) had HbA1c < 7%, 
68 (27%) had HbA1c ≥ 9%, and 173 (71%) had LDL < 100mg/dL. Although 74 patients 
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objeCtives: To assess the effectiveness, tolerability and maintenance of vildaglip-
tin in type 2 diabetes (T2D) patients under real-life conditions in France, requested 
by the French Health Technology Agency. Methods: A representative sample of 
T2D patients initiating a treatment with vildagliptin was enrolled in a 2 years fol-
low-up observational cohort in 2010 by a national sample of endocrinologists and 
general practitioners. Results: A total of 482 GPs and 84 endocrinologists included 
1,700 patients. 60% were males, mean age= 63 (±9) years, mean disease duration= 7 
(±6.5) years. Follow up visits were available for 96.3%, 90.7%, 86.5% and 81.8% of 
patients at respectively 6, 12 18 and 24 months. Mean HbA1c level decreased from 
7.8% (sd= 1.3) before vildagliptin prescription to 7.0% (sd= 1.0) 0 to 6 months after 
vildagliptin initiation and remained stable thereafter: 7.0% (sd= 1.0), 7.0% (sd= 0.9) 
and 7.0% (sd= 1.0) 6 to 12 months, 12 to 18 months and 18 to 24 months after vilda-
gliptin initiation. The percentages of patients with alanine and/or aspartate ami-
notransferase above 120 UI were 0.5% before vildagliptin prescription and 0.3%, 0.5%, 
0.1%, 0.0% at 0-6 months, 6-12 months, 12-18 months and 18-24 months after vilda-
gliptin prescription. The mean glomerular filtration rate (MDRD formula) was 82.0 
ml/minute before vildagliptin prescription and 82.4, 84.1, and 83.6 and 82.8, at 0-6 
months, 6-12 months, 12-18 months and 18-24 months after vildagliptin prescrip-
tion. The incidence of severe hypoglycemia (requiring third party assistance) has 
been estimated at 0.30/100 vildagliptin treated patients years (CI95%= [0.15,0.55]). 
All occurred in patients also treated with insulin and/or sulfamide The proportion 
of patients treated with vildagliptin remained high over the course of the study: 
96.5% (CI95%[95.6,97.4]) after 6 months, 92.5% (CI95%= [91.2%,93.8%]) after one year 
and 88.8% (CI95%= [87.2%,90.4%]) after 2 years. ConClusions: Vildagliptin showed 
sustained effectiveness in terms of reduction in HbA1c over 24 months, with a low 
incidence of hypoglycemia.
PDB14
clinicAl outcomeS AnD heAlth cARe coStS evAluAtion of 
SulfonAmiDeS AnD thiAzoliDineDioneS comPAReD with DiPePtiDyl 
PePtiDASe 4 inhiBitoRS foR the tReAtment of uncontRolleD DiABeteS
Degli Esposti L., Saragoni S., Buda S., Degli Esposti E.
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objeCtives: To compare clinical outcomes and the health care costs across 
two cohorts of uncontrolled diabetic patients who initiated treatment with 
Sulfonamides or Thiazolidinediones (SU/TZD) or Dipeptidyl Peptidase 4 (DPP-4) 
Inhibitors in a clinical practice setting. Methods: A retrospective analysis using a 
large administrative database and a clinical registry containing laboratory results 
of three Italian Local Health Units was performed. The index-period ranged from 
July, 2008 and June, 2010. Patients were treatment naïve to SU/TZD or to DPP-4, 
but already treated with other oral antidiabetic agents. Demographics, concomi-
tant therapies, Charlson comorbidity index, glycemic and lipid control level and 
previous hospitalizations were assessed at baseline. Adherence was measured 
by Medication Possession Ratio (MPR). We calculated unadjusted rates and used a 
Poisson regression model to estimate risk ratios for diabetes-related hospitaliza-
tions occurred during the 18-months follow-up period. Total annual costs included 
all the pharmacological treatments and the direct costs due to hospitalizations 
and outpatient services. Results: We identified 1384 patients treated with SU/
TZD and 199 treated with DPP-4. DPP-4 patients were significantly younger (mean 
age 59.2 years and 65.0 years; p< 0.001) and with less previous hospital discharges 
for diabetes-related diseases. Baseline mean HbA1c was 8.1% for SU/TZD and 
8.2% for DPP-4 patients. DPP-4 naïve resulted more adherent (MPR≥ 80%) than SU/
TZD naïve (70.9% and 55.8%; p< 0.001). The SU/TZD group showed a significant 
increased risk of diabetes-related hospitalizations (unadjusted rate was 9,17 vs 
3,47 per 100 person-years, p= 0.002; adjusted incidence rate ratio 1.83; p= 0.028). 
The higher hospitalization rate resulted in higher total annual direct costs per 
patient (€ 2.719 vs € 2.462 of those treated with DPP-4). ConClusions: Results 
indicate that uncontrolled diabetic patients who initiated treatment with DPP-4, 
compared with those initiating with SU/TZD, are associated with a reduced risk 
of diabetes-related hospitalizations and consequently with a lower overall total 
annual cost per patient.
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the PReSence of metABolic AnD otheR RiSk fActoRS in ADRenAl 
inSufficiency PAtientS comPAReD to An unmAtcheD BAckgRounD 
PoPulAtion fRom the SAme Region in the uniteD kingDom
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objeCtives: To describe epidemiological characteristics among adrenal insufficiency 
(AI) patients and describe the prevalence of risk factors in primary and secondary AI 
(PAI; SAI) and an unmatched, non-AI population. These analyses explore metabolic 
morbidity in AI, which literature suggests may be associated to a non-physiological 
cortisol profile. Methods: Initial aggregated data from the FARSITE database were 
analysed. The prevalence of risk factors was evaluated, including hypertension, BMI, 
diabetes and depression, and compared across PAI, SAI and non-AI populations. 
Characteristics of non-AI patients were not matched with AI patients. Results: A 
total of 261,638 patients were included; 62 PAI and 191 SAI. Prevalence of hypertension 
was 32% in PAI, 22% in SAI and 13% non-AI. 26% of hypertension in SAI was not on 
target according to QOF criteria (14% non-AI; 10% PAI). Hypercholesterolemia occurred 
in 13% of PAI and 6% of SAI patients (3% non-AI). Among SAI patients, 69% were over-
weight (BMI> 25) or obese (BMI> 30) (63% PAI; 39% non-AI). Diabetes (Type 1 and 2) was 
prevalent in 13% of PAI and 10% of SAI (5% non-AI), with HbA1c not controlled accord-
ing to QOF criteria in 75% of PAI and 74% of SAI patients. Psychological risk factors 
were more prevalent among AI patients; 24% of PAI and 14% of SAI patients recently 
received anti-anxiety/depression treatment (6% non-AI). Hypnotics were recently 
prescribed to 6% of SAI patients (1% non-AI; PAI not reported). Bisphosphonates are 
used by 21% of PAI and 8% of SAI patients (2% non-AI). The hospital admission rate 
was 3% for SAI patients (1% non-AI; PAI not reported). ConClusions: The preva-
lence of metabolic and other risk factors is considerably higher among AI patients 
indirect pairwise odds ratios (OR) were obtained. The study used Bayesian Analysis 
Using Gibbs Sampling in Windows (WinBUGS) version 1.4.3. and Monte Carlo 
Simulations to conduct a multiple treatment comparison. Results are reported in 
OR with 95% credible intervals (CI) and the median of ranking. Results: There were 
a total of 10 studies with 23 treatment arms, representing 2,885 subjects enrolled, 
that were included in the analysis. The results from fix effects model indicated 
that duloxetine, pregabalin, gabapentin, and co-administration of duloxetine and 
gabapentin were significantly better than amitriptyline (OR= 3.22[95%CI, 1.54-7.17], 
OR = 2.53[95%CI, 1.11-5.94], OR = 4.00[95%CI, 1.33-11.69], OR = 2.86[95%CI, 1.09-7.48], 
respectively). The results from random effects model suggested that only duloxetine 
and pregabalin were significantly better than placebo (OR = 2.61[95%CI, 1.37-4.95] 
and OR = 1.97[95%CI, 1.01-3.62], respectively). There was no significant difference 
between amitriptyline and placebo in either fixed or random effects models. With 
regard to the median ranking, gabapentin was ranked first, followed by duloxetine, 
co-administration of duloxetine and gabapentin, pregabalin, placebo, and amitrip-
tyline from the fix effects model. ConClusions: Treatment of PDPN with amitrip-
tyline does not appear to be significantly different from placebo. Duloxetine and 
pregabalin appear to be better than both amitriptyline and placebo.
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objeCtives: The GALATA study was the first observational study on DPP-4 inhibitors in 
Turkey and aimed to evaluate the efficacy, safety and tolerability of vildagliptin and met-
formin combination (VMc) in patients with type 2 diabetes mellitus (T2DM). Methods: 
A total of 648 of the 682 screened T2DM outpatients (age > 18 years) on VMc for at least 
4 weeks prior to enrollment were included in this 24-week, multicenter, observational 
study. Results: Of the 648 patients, 382 (59.0%) were female. The mean (standard devi-
ation-SD-) age was 55.2 (10.2) years, the mean (SD) T2DM duration was 4.8 (5.2) years and 
220 (34.0%) patients had T2DM for more than 5 years. Patients were followed for median 
(inter-quartile range-IQR-) 184.0 (74.0) days at median (IQR) 4.0 (2.0) visits. Median vilda-
gliptin and metformin doses were 100.0 mg and 2000 mg, respectively. HbA1c decreased 
from 7.8% to 7.0% (p< 0.001). A similar reduction in HbA1c from 7.6% to 7.1% was also seen 
in elderly patients (> 65 years, 18.1% of patients) (p< 0.001). The proportion of patients 
with HbA1c ≤ 6.5% increased from 13.3% to 42.7% (p< 0.001) and those with HbA1c ≤ 7.0% 
increased from 26.6% to 65.3% (p< 0.001). Mean fasting plasma glucose (FPG) decreased 
from 153.1 mg/dL to 136.5 mg/dL (p< 0.001), whereas mean post-prandial plasma glucose 
(PPG) decreased from 217.6 mg/dL to 182.1 mg/dL (p< 0.001). Eighty (12.3%) patients expe-
rienced 122 adverse events (AEs) including 3 serious AEs; 2 SAEs were not suspected to 
be related to VMc. AEs were mostly (94.3%) mild or moderate in severity and no action 
was taken for 44.3% of them; 76.2% of AEs resolved during follow-up. ConClusions: 
The results of the GALATA study suggested that VMc significantly decreased HbA1c, FPG 
and PPG, achieved glycemic control targets even in elderly patients and demonstrated 
good overall safety and tolerability in T2DM patients.
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efficAcy AnD SAfety of tReAtmentS of tyPe 2 DiABeteS mellituS 
(t2Dm): A SyStemAtic Review (SlR)
Pettré S.1, Selya-Hammer C.1, Ho S.1, Garg M.2, Schroeder M.3, Kaur V.4, Hemels M.2
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objeCtives: Collect randomized clinical evidence on the efficacy and safety of anti-
diabetic agents used in dual or triple therapy or add-on to insulin to provide a qualita-
tive overview of the available evidence and undertake a meta-analysis. Methods: 
A SLR was conducted in line with NICE guidelines to identify randomised controlled 
trials assessing agents received in combination with metformin (MET), a sulphony-
lurea (SU), MET+SU, MET+pioglitazone, or insulin. Interventions of interest included 
SGLT-2 inhibitors (canagliflozin and dapagliflozin), sulphonylureas, pioglitazone, 
DDP-4 inhibitors, GLP-1 analogues and insulin. Electronic searches were undertaken 
using Medline, Medline-in-process, Embase, and the Cochrane Library and supple-
mented with hand searches. An ad hoc search was conducted to identify the most 
recent data at 104 weeks. Results: A total of 159 clinical trials met inclusion criteria. 
The frequency of studies by background therapy was as follows: MET (38%), mixed 
(trials containing treatment arms with different background therapies; 25%), insulin 
(21%), MET+SU (9%), and SU alone (8%). One study (assessing canagliflozin) featured 
a background of MET+pioglitazone. Studies varied in terms of treatment duration (12 
to 104 weeks), presence and duration of run-in periods (57% studies with run-in, from 
0.7 to 18 weeks), HbA1c eligibility criteria (minimum from 6% to 7%), body mass index 
(BMI; 37 studies focused on overweight and obese patients, two studies focused on 
obese patients) and age for inclusion (from ≥ 18 to ≤ 85 years). ConClusions: The 
outcome of this SLR will serve as input-data in a meta-analysis, to assess relative 
efficacy of T2DM treatments in different background therapy settings.
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